The isolation of single monoclonal antibodies (mAbs) against a given antigen was only possible with the introduction of the hybridoma technology, which is based on the fusion of specific B lymphocytes with myeloma cells. Since then, several mAbs were described for therapeutic, diagnostic, and research purposes. Despite being an old technique with low complexity, hybridoma-based strategies have limitations that include the low efficiency on B lymphocyte-myeloma cell fusion step, and the need to use experimental animals. In face of that, several methods have been developed to improve mAb generation, ranging from changes in hybridoma technique to the advent of completely new technologies, such as the antibody phage display and the single B cell antibody ones. In this review, we discuss the hybridoma technology along with emerging mAb isolation approaches, taking into account their advantages and limitations. Finally, we explore the usefulness of the hybridoma technology nowadays.
Keywords: ASC, antibody-secreting cell; Antibody phage display; B cell targeting; BCT, B cell targeting; CDR, complementarity determining region; Fab, antigen-binding fragment; Hybridoma; Monoclonal antibody; PEF, pulsed electric field; PEG, polyethylene glycol; SST, stereospecific targeting; Single B cell Antibody technology; Stereospecific targeting; VH, heavy chain variable domain; VL, light chain variable domain; cDNA, complementary DNA; mAb, monoclonal antibody; scFv, single-chain variable fragment.
© 2021 The Author(s).